-
Something wrong with this record ?
Antibody-mediated rejection of renal allografts: diagnostic pitfalls and challenges
M. Novotný, M. Kment, O. Viklický
Language English Country Czech Republic
Document type Journal Article
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
PubMed Central
from 2020
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- Allografts MeSH
- Isoantibodies MeSH
- Kidney pathology MeSH
- Humans MeSH
- Graft Rejection diagnosis MeSH
- Kidney Transplantation * adverse effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Antibody-mediated rejection (ABMR) is a major obstacle to the long-term success in kidney transplantation. Diagnosis of ABMR is determined according to the internationally recognized Banff criteria. However, a significant proportion of patients does not meet all the defined criteria, and the outcome of such cases remains poorly understood. The histology of ABMR frequently lacks sensitivity and specificity. More importantly, mixed forms of ABMR and T cell-mediated rejection as well as findings of nonspecific injury are common in clinical settings. Donor-specific anti-HLA antibodies (DSA) are detectable only in half of the ABMR cases by histology. Prognostic role of non-HLA antibodies against various endothelial proteins has been discussed. Antibody independent NK cell activation reflecting killer-cells' inhibitory receptor incompatibility is suggested in microvascular inflammation in DSA negative patients. Molecular assessment of ABMR has been prioritized to overcome high interobserver variability and improve diagnostics in mixed forms of rejections and in DSA negative cases. Finally, donor-derived cell-free DNA detected in a recipient's peripheral blood sample has been proposed as a noninvasive marker for diagnosis of graft rejection, and thus might serve as a liquid biopsy in the near future. Despite all achievements, diagnosing ABMR in kidney allografts remains to be a challenge in a significant number of cases.
1st Medical Faculty Charles University Prague Czech Republic
Department of Nephrology Institute for Clinical and Experimental Medicine Prague Czech Republic
Transplant Laboratory Institute for Clinical and Experimental Medicine Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22009503
- 003
- CZ-PrNML
- 005
- 20250610144312.0
- 007
- ta
- 008
- 220419s2021 xr a f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.934801 $2 doi
- 035 __
- $a (PubMed)35199543
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Novotný, Marek $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $7 xx0213626 $u 1st Medical Faculty, Charles University, Prague, Czech Republic
- 245 10
- $a Antibody-mediated rejection of renal allografts: diagnostic pitfalls and challenges / $c M. Novotný, M. Kment, O. Viklický
- 520 9_
- $a Antibody-mediated rejection (ABMR) is a major obstacle to the long-term success in kidney transplantation. Diagnosis of ABMR is determined according to the internationally recognized Banff criteria. However, a significant proportion of patients does not meet all the defined criteria, and the outcome of such cases remains poorly understood. The histology of ABMR frequently lacks sensitivity and specificity. More importantly, mixed forms of ABMR and T cell-mediated rejection as well as findings of nonspecific injury are common in clinical settings. Donor-specific anti-HLA antibodies (DSA) are detectable only in half of the ABMR cases by histology. Prognostic role of non-HLA antibodies against various endothelial proteins has been discussed. Antibody independent NK cell activation reflecting killer-cells' inhibitory receptor incompatibility is suggested in microvascular inflammation in DSA negative patients. Molecular assessment of ABMR has been prioritized to overcome high interobserver variability and improve diagnostics in mixed forms of rejections and in DSA negative cases. Finally, donor-derived cell-free DNA detected in a recipient's peripheral blood sample has been proposed as a noninvasive marker for diagnosis of graft rejection, and thus might serve as a liquid biopsy in the near future. Despite all achievements, diagnosing ABMR in kidney allografts remains to be a challenge in a significant number of cases.
- 650 _2
- $a alografty $7 D064591
- 650 _2
- $a rejekce štěpu $x diagnóza $7 D006084
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a isoprotilátky $7 D007518
- 650 _2
- $a ledviny $x patologie $7 D007668
- 650 12
- $a transplantace ledvin $x škodlivé účinky $7 D016030
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kment, Martin $7 xx0171983 $u Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Viklický, Ondřej, $d 1966- $7 nlk20050170291 $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u 1st Medical Faculty, Charles University, Prague, Czech Republic
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 70, Suppl. 4 (2021), s. S551-S565
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35199543 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y p $z 0
- 990 __
- $a 20220419 $b ABA008
- 991 __
- $a 20250610144305 $b ABA008
- 999 __
- $a ok $b bmc $g 1797011 $s 1160701
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 70 $c Suppl. 4 $d S551-S565 $e 20211230 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- LZP __
- $b NLK124 $a Pubmed-20220419